Introduction {#s1}
============

Management of chronic postsurgical pain remains a challenge for anesthesiologists and surgeons. Approximately 240 million surgical procedures are performed worldwide each year, and an estimated 12% of patients still report moderate to intense pain 1 year after surgery (Fletcher et al., [@B13]). Inadequately treated pain could be considered an adverse postoperative effect, as it can lead to longer hospital stays, higher costs, and lower patient satisfaction (Shipton, [@B51]). Acute postoperative pain is also a risk factor for the development of chronic postsurgical pain (Perkins and Kehlet, [@B44]), and the relationship appears to be directly proportional, with more intense or longer-lasting pain linked to a higher incidence of chronic pain (Mion and Villevieille, [@B39]; Pozek et al., [@B45]; Reddi, [@B46]).

Remifentanil is a widely used general anesthesia thanks to its pharmacodynamic and pharmacokinetic properties (Kim et al., [@B26]). Its potency as an opioid agonist combined with a short elimination half-life without accumulating with prolonged infusion allows anesthesiologists to maintain hemodynamic stability during surgery without risk of delayed awakening. Intraoperative remifentanil infusion has, however, been associated with opioid-induced hyperalgesia (Joly et al., [@B23]; Fletcher and Martinez, [@B12]).

The N-methyl-D-aspartate (NMDA) receptor is believed to play an important role in the pathophysiology of opioid-induced hyperalgesia (Mao et al., [@B35]; Mayer et al., [@B36]; Williams et al., [@B57]; Ossipov et al., [@B42]; Angst and Clark, [@B1]; Mao, [@B34]). Ketamine is a non-competitive NMDA receptor antagonist (Mion and Villevieille, [@B39]) authorized by the U.S. Food and Drug Administration as an anesthetic drug and it is used in multimodal analgesia regimens to improve postoperative pain control (Chou et al., [@B9]). The classic anesthetic effect of ketamine is described as a dose-dependent central nervous system (CNS) depression that leads to a dissociative state characterized by profound analgesia and amnesia but not necessarily loss of consciousness (Kohrs and Durieux, [@B28]). The use of low subanesthetic doses of ketamine (no more than 1 mg/kg iv bolus or 20 μg/kg/min continuous infusion) as an adjuvant to morphine in postoperative multimodal analgesia regimens (Schmid et al., [@B49]) is supported by several lines of evidence: (i) the mechanism of action of ketamine and the importance of the NMDA neurotransmission system in nociceptive processing (Bell et al., [@B5]); (ii) evidence that ketamine potentiates the analgesic effects of opioids, suggesting that it could reduce acute postoperative pain and minimize opioid consumption (Carstensen and Möller, [@B6]; Song et al., [@B53]); and (iii) the low toxicity of subanesthetic doses of ketamine (Michelet et al., [@B38]). In addition, recent studies have attributed additional antihyperalgesic, neuroprotective, antidepressant, and anti-inflammatory effects to ketamine based on its interaction with multiple other receptors, such as AMPA, kainate, gamma-aminobutyric acid (GABA), opiate, muscarinic, as well as voltage-gated sodium and hyperpolarization-activated cyclic nucleotide-gated channels (Zanos et al., [@B61]). The isomer *S*(+)-ketamine (also named Esketamine) is reported to be twice as potent as the racemic mixture as an anesthetic (Zanos et al., [@B61]). Despite these seemingly "ideal" qualities of ketamine, however, contradictory results have been reported for the efficacy of ketamine in multimodal perioperative analgesia regimens.

We wondered if there was clinical evidence supporting the use of perioperative ketamine to improve postoperative pain after remifentanil-based anesthesia in adults. To our knowledge, only two meta-analyses, each analyzing 14 randomized controls trials (RCTs), have been conducted (Liu et al., [@B32]; Wu et al., [@B58]) and they reported conflicting findings One of the analyses found no significant evidence that NMDA antagonists prevented remifentanil-associated hyperalgesia (Wu et al., [@B58]), while the other one showed that ketamine significantly reduced postoperative pain and cumulative morphine consumption (Wu et al., [@B58]). This benefit was also found in a meta-analysis of the addition of ketamine to morphine in patient-controlled analgesia devices (Assouline et al., [@B2]). The contradictory results could be partly due to the fact that the meta-analyses did not distinguish between different types of surgery.

The aim of this systematic review and meta-analysis was to evaluate the influence of perioperative ketamine within a multimodal analgesia regimen in adults undergoing surgery, distinguishing between minor and major procedures and excluding studies of NMDA antagonists other than ketamine to minimize confounding and heterogeneity.

Materials and methods {#s2}
=====================

We performed a systematic review of the literature in accordance with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement.

Eligibility criteria
--------------------

An initial database search was undertaken to identify RCTs examining the use of perioperative low-dose ketamine in remifentanil-based general anesthesia for major or minor surgery. Only studies that were performed in adults and used morphine as a postoperative analgesic were eligible for inclusion. RCTs reporting on postoperative cumulative morphine consumption, pain intensity, pain outcomes, and adverse opioid or ketamine effects were considered.

Information sources and search
------------------------------

A search of the PubMed, Web of Science, Scopus, and Cochrane databases was performed in June 2017. Only articles written in English or Spanish were included. The search queries used for each database are shown in Table [1](#T1){ref-type="table"}.

###### 

Search strategies and results in each bibliographic database.

  -------------------------------------------------------------------------------------------------------------------------------
  **Database**     **Search Query**                                                                                 **Results**
  ---------------- ------------------------------------------------------------------------------------------------ -------------
  PubMed           (("Remifentanil" \[Supplementary Concept\]) AND "Ketamine"\[Mesh\]) AND "Hyperalgesia"\[Mesh\]   19

  Cochrane         Remifentanil AND Ketamine AND Hyperalgesia Refined by: Document Types: Trials                    36

  Web of science   TS = (Remifentanil AND Ketamine AND Hyperalgesia)\                                               57
                   Refined by: Databases: Core Collection AND Document Types: Clinical Trials                       

  Scopus           TITLE-ABS-KEY (Remifentanil AND Ketamine AND Hyperalgesia)\                                      58
                   Refined by: Document Types: Articles                                                             
  -------------------------------------------------------------------------------------------------------------------------------

Study selection
---------------

Two reviewers (JFGH and JAMM) independently performed the search and assessed the suitability of the articles for inclusion. In the event of disagreement, the reviewers discussed the discrepancies and decided whether or not to include the article. If they were unable to reach an agreement, a third reviewer (AS) was involved. In a pre-selection phase, the abstracts of all the articles retrieved by the literature search were screened for eligibility. Potentially eligible studies were then assessed in depth by examining the full text prior to inclusion.

Data collection process
-----------------------

Relevant data from selected articles were extracted and recorded in a purpose-designed spreadsheet by a single author (JFGH) using a standardized procedure. The authors of one original article that met the inclusion criteria but had some missing information on means and standard deviation were contacted twice by e-mail, but they did not reply (Hong et al., [@B21]). The information extracted by JFGH was independently reviewed by two authors (JAMM and AS).

Data items
----------

The following data were extracted from each study: study design, study population, ketamine and remifentanil regimens, description of the intervention or control and experimental groups, type of surgical procedure, postoperative analgesia strategies, follow-up period, and outcome measures (Table [2](#T2){ref-type="table"}).

###### 

Details of the selected studies.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Author**        **Year**   **Sample size (K/control)**   **Ketamine protocol**                                               **Remifentanil infusion rate**   **Procedure**                  **N20**   **Anesthesia maintenance**   **Postoperative analgesia**
  ----------------- ---------- ----------------------------- ------------------------------------------------------------------- -------------------------------- ------------------------------ --------- ---------------------------- -------------------------------------------------------------------
  Aubrun et al.     [@B3]      45/45                         0.5 mg/kg iv before surgical incisión + 5 mg/ml postoperative PCA   0.5 μg/kg/min                    Gynecological surgery          NO        Propofol                     Morphine PCA

  Ganne et al.      [@B14]     30/31                         0.15 mg/kg iv + 2 μg/kg/min                                         0.25 μg/kg/min                   ENT surgery                    NO        Propofol                     Morphine PCA+ Paracetamol 1 g/6 h+ methylprednisolone 2 mg/kg/dia

  Guignard et al.   [@B18]     25/25                         0.15 mg/kg iv + 2 μg/kg/min                                         0.25 μg/kg/min                   Open colorrectal surgery       NO        Desfluorane                  Morphine PCA

  Hadi et al.       [@B19]     30/15                         1 μg/kg/min (±1 μg/kg/min postoperative)                            0.2 μg/kg/min                    Lumbar microdiscectomy         Yes       Sevofluorane                 Morphine PCA

  Hadi et al.       [@B20]     15/15                         1 μg/kg/min                                                         0.2 μg/kg/min                    Spinal fusion                  YES       Sevofluorane                 Morphine Pump

  Jaksch et al.     [@B22]     15/15                         0.5 mg/kg iv + 2 μg/kg/min                                          0.5 μg/kg/min                    Arthroscopic ACL repair        NO        Propofol                     Morphine PCA

  Joly et al.       [@B23]     24/25                         0.5 mg/kg iv +5 μg/kg/min+\                                         0.4 μg/kg/min                    Abdominal surgery              NO        Desfluorane                  Morphine PCA
                                                             2 μg/kg/min postoperative infusion                                                                                                                                         

  Leal et al.       [@B30]     28/28                         5 μg/kg/min                                                         0.4 μg/kg/min                    Laparoscopic cholecystectomy   NO        Isoflourane                  Morphine PCA

  Lee et al.        [@B31]     20/20                         0.3 mg/kg+ 3 μg/kg/min                                              4 ng/ml                          Laparoscopic cholecystectomy   NO        Sevofluorane                 Morphine PCA

  Sahin et al.      [@B48]     17/16                         0.5 mg/kg iv                                                        0.1 μg/kg/min                    Lumbar disk operation          YES       Desfluorane                  Morphine PCA

  Van Elstraete     [@B54]     20/20                         0.5 mg/kg iv + 2 μg/kg/min                                          0.25 μg/kg/min                   Tonsillectomy                  NO        Propofol                     Morphine i.v.

  Yalcin et al.     [@B59]     30/30                         0.5 mg/kg                                                           0.4 μg/kg/min                    Total abdominal hysterectomy   NO        Desfluorane                  Morphine PCA
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Primary endpoints were cumulative morphine consumption (mg) in the first 24 h and pain intensity at 0, 2, 4, 12, and 24 h. Pain intensity was statistically standardized on a 0--10 cm visual analog scale (VAS). Due to the small number and heterogeneous nature of the articles selected, there were only two secondary endpoints: time to the first rescue analgesia and presence of ketamine or opioid adverse effects. Patient satisfaction and psychotic adverse effects in minor surgery were excluded from the meta-analysis as we were unable to obtain the missing data from the authors.

Risk of bias
------------

The methodological quality of the RCTs was analyzed using the PEDro (Maher et al., [@B33]) and Jadad (Clark et al., [@B11]) scales. The PEDro scale is an 11-item scale that assesses (i) notification of selection criteria, (ii) allocation of subjects to groups at random, (iii) concealment of allocation, (iv) similarity among groups at baseline in relation to the most important prognostic indicators, (v) blinding of participants, (vi) blinding of researchers/therapists, (vii) blinding of researchers measuring at least one key outcome, (viii) proportion of initial participants that contribute measures to the key results, (ix) compliance of the intervention assigned by the participants, (x) presentation of statistical comparisons between the groups, and (xi) presentation of specific measures and variability of the key results. One point is assigned to each criterion, except for (i), which is not included in the final score. The total possible score thus ranges from 0 to 10. Scores of 9 to 10 indicate excellent quality, 6to 8 good quality, 4 to 5 fair quality, and \<4 poor quality (Gordt et al., [@B16]). With the Jadad scale, studies receive a score of 0--5 points (with higher scores representing higher methodological quality) depending on whether they (i) are described as randomized or doubled blind, (ii) use an appropriate randomization sequence or blinding procedure, and (iii) provide detailed information on withdrawals and dropouts. As studies of low methodological quality may overestimate treatment benefits (Moher et al., [@B40]), we only included studies with a PEDro score of 6 or higher (Clark et al., [@B11]) and a Jadad score of 3 or higher (Kang et al., [@B24]; Annex 1 in [Supplementary Material](#SM1){ref-type="supplementary-material"}).

Statistical analysis
--------------------

The 12 RCTs were grouped into 16 subgroups according to effect size and type of surgery (major or minor) (Table [3](#T3){ref-type="table"}). A study could belong to more than one group if it reported more than one effect size or it analyzed both major and minor surgery. Studies could also appear more than once in the same subgroup if they performed comparisons with different groups under the same conditions.

###### 

Characteristics of subgroups included in the meta-analysis.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Subgroup**                            **Trials included**                     **Effect size**                      **Heterogeneity test**                   **Model**        **Publication bias[^\*^](#TN1){ref-type="table-fn"}**
  --------------------------------------- --------------------------------------- ------------------------------------ ---------------------------------------- ---------------- -------------------------------------------------------
  1                                       Van Elstraete et al., −30 min [@B55]\   VAS 0--2 h\                          Heterogeneity\                           Random effects   No bias\
                                          Leal et al., −30 min [@B30]\            Minor surgery                        *Q* = 225.2737; *df* = 5; *p* \< 0.001                    *Z* = 1.5029; *p* = 0.1329\
                                          Van Elstraete et al., −1 h [@B55]\                                                                                                     *T* = −1.3473; *p* = 0.2492
                                          Leal et al., −1 h [@B30]\                                                                                                              
                                          Van Elstraete et al., −2 h [@B55]\                                                                                                     
                                          Leal et al., −2 h [@B30]                                                                                                               

  2                                       Assouline et al., −1 h ([@B22])\        VAS 0--2 h\                          Homgeneity\                              Fixed effects    No bias\
                                          Jaksch et al., −2 h ([@B22])\           Major surgery                        *Q* = 1.1184; *df* = 2; *p* = 0.5717                      *Z* \< 0.001; *p* \> 0.999\
                                          Aubrun et al., 0--30 min ([@B3])                                                                                                       *T* = 1.2596; *p* = 0.4272

  3                                       Van Elstraete et al., [@B55]\           VAS4 h\                              Heterogeneity\                           Random effects   --
                                          Leal et al., [@B30]                     Minor surgery                        *Q* = 14.7884; *df* = 1; *p* = 0.001                      

  4                                       Joly et al., [@B23]\                    VAS 4 h\                             Heterogeneity\                           Random effects   No bias\
                                          Ganne et al., [@B14]\                   Major surgery                        *Q* = 21.5624; *df* = 2; *p* \< 0.001                     *Z* \< 0.001; *p* \> 0.999\
                                          Aubrun et al., [@B3]                                                                                                                   *T* = −0.6603; *p* = 0.6285

  5                                       Van Elstraete, [@B54]\                  VAS 12 h\                            Heterogeneity\                           Random effects   Bias\
                                          Hadi et al., [@B19]\                    Minor surgery                        *Q* = 104.3763; *df* = 3; *p* \< 0.001                    *Z* = 1.6984; *p* = 0.0894\
                                          Hadi et al., [@B19]\                                                                                                                   *T* = −7.5979; *p* = 0.0169
                                          Leal et al., [@B30]                                                                                                                    

  6                                       Joly et al., [@B23]\                    VAS 12 h\                            Heterogeneity\                           Random effects   No bias\
                                          Ganne et al., [@B14]\                   Major surgery                        *Q* = 81.4968; *df* = 2; *p* \< 0.001                     *Z* = 1.0445; *p* = 0.2963\
                                          Aubrun et al., [@B3]                                                                                                                   *T* = 2.0911; *p* = 0.2840

  7                                       Van Elstraete, [@B54]\                  VAS 24 h\                            Heterogeneity\                           Random effects   No bias\
                                          Hadi et al., [@B19]\                    Minor surgery                        *Q* = 197.5201; *df* = 3; *p* \< 0.001                    *Z* = 1.6984; *p* = 0.0894\
                                          Hadi et al., [@B19]\                                                                                                                   *T* = −2.1538; *p* = 0.1641
                                          Leal et al., [@B30]                                                                                                                    

  8                                       Joly et al., [@B23]\                    VAS 24 h\                            Heterogeneity\                           Random effects   No bias\
                                          Ganne et al., [@B14]\                   Major surgery                        *Q* = 71.2937; *df* = 2; *p* \< 0.001                     *Z* = 1.0445; *p* = 0.2963\
                                          Aubrun et al., [@B3]                                                                                                                   *T* = 3.5866; *p* = 0.1731

  9                                       Van Elstraete, [@B54]\                  Morphine consumption minor surgery   Heterogeneity\                           Random effects   Bias\
                                          Hadi et al., [@B19]\                                                         *Q* = 118.7848; *df* = 3; *p* \< 0.001                    *Z* = 1.6984; *p* = 0.0894\
                                          Hadi et al., [@B19]\                                                                                                                   *T* = −16.5343; *p* = 0.0036
                                          Leal et al., [@B30]                                                                                                                    

  10                                      Sahin et al., [@B48]\                   Morphine consumption major surgery   Heterogeneity\                           Random effects   Bias\
                                          Ganne et al., [@B14]\                                                        *Q* = 326.9692; *df* = 5; *p* \< 0.001                    *Z* = 1.5029; *p* = 0.1329\
                                          Aubrun et al., [@B3]\                                                                                                                  *T* = −5.3088; *p* = 0.0061
                                          Hadi et al., [@B20]\                                                                                                                   
                                          Guignard et al., [@B18]\                                                                                                               
                                          Yalcin et al., [@B59]                                                                                                                  

  11                                      Van Elstraete, [@B54]\                  Time to first rescue analgesia\      Heterogeneity\                           Random effects   Bias\
                                          Hadi et al., [@B19]\                    Minor surgery                        *Q* = 105.1229; *df* = 2; *p* \< 0.001                    *Z* = 1.0445; *p* = 0.2963\
                                          Hadi et al., [@B19]                                                                                                                    *T* = 419.7603; *p* = 0.0015

  12                                      Jaksch et al., [@B22]\                  Time to first rescue analgesia\      Heterogeneity\                           Random effects   No bias\
                                          Guignard et al., [@B18]\                Major surgery                        *Q* = 225.8723; *df* = 3; *p* \< 0.001                    *Z* = 0.3397; *p* = 0.7341\
                                          Sahin et al., [@B48]\                                                                                                                  *T* = 3.6662; *p* = 0.0670
                                          Joly et al., [@B23]                                                                                                                    

  13                                      Van Elstraete, [@B54]\                  PONV\                                Heterogeneity\                           Random effects   No bias\
                                          Hadi et al., [@B19]\                    Minor surgery                        *Q* = 3.9975; *df* = 3; *p* = 0.2617                      *Z* = −0.3397; *p* = 0.7341\
                                          Hadi et al., [@B19]\                                                                                                                   *T* = −0.2830; *p* = 0.8038
                                          Leal et al., [@B30]                                                                                                                    

  14                                      Guignard et al., [@B18]\                PONV\                                Homogeneity\                             Fixed effects    No bias\
                                          Jaksch et al., [@B22]\                  Major surgery                        *Q* = 1.7537; *df* = 4; *p* = 0.7809                      *Z* = 0.7348; *p* = 0.4624\
                                          Joly et al., [@B23]\                                                                                                                   *T* = 1.0131; *p* = 0.3856
                                          Ganne et al., [@B14]\                                                                                                                  
                                          Aubrun et al., [@B3]                                                                                                                   

  15[^\*\*^](#TN2){ref-type="table-fn"}   Van Elstraete, [@B54]\                  Psychotic events minor surgery       --                                       --               --
                                          Hadi et al., [@B19]\                                                                                                                   
                                          Hadi et al., [@B19]\                                                                                                                   
                                          Leal et al., [@B30]                                                                                                                    

  16                                      Jaksch et al., [@B22]\                  Psychotic events major surgery       Homogeneity\                             Fixed effects    --
                                          Aubrun et al., [@B3]                                                         *Q* = 0.1108; *df* = 1; *p* = 0.7393                      
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*Results not shown for subgroups with only two studies. PONV, postoperative nausea and vomiting; VAS, visual analog scale*.

*Results not shown for subgroup 15, which was not included in the meta-analysis*.

The effect sizes considered were pain intensity measured on a 10-point VAS, where 0 indicated no pain and 10 indicated the worst possible pain; morphine consumption (mg); time to first rescue with analgesia (minutes); incidence of postoperative nausea and vomiting (PONV); and incidence of ketamine-related adverse events. All the RCTs compared the administration of ketamine and morphine (intervention group) vs. morphine only (control group).

A meta-analysis was carried out in each subgroup to compare the effect size between the intervention and control group. Standardized mean differences (SMDs) and 95% confidence intervals (CIs) were used for continuous variables (VAS, morphine consumption, and time to first rescue analgesia), while relative risk (RR) and 95% CIs were used for the incidence of PONV and psychotic events (anxiety, visual disturbances, impairment of cognitive functioning or florid psychotics symptoms like delirium or hallucinations). The significance level was set at *p* \< 0.05.

Heterogeneity was determined using the Dersimonian and Laird test and the Cochran Q statistic. A fixed-effects model was used for studies with homogeneity and a random-effects model was used when there was significant heterogeneity. The latter accounts for variability due to differences between studies. The results of the meta-analyses are shown in forest plots. The plots show the differences between the intervention and control groups for mean values, and RRs, showing overall measures, together with the corresponding confidence intervals. Publication bias was analyzed (only in subgroups with three or more studies) using the Begg test (Z statistic) and the Egger test (t statistic). Finally, a sensitivity analysis was carried out to study the contribution of each study to the overall effect estimate. The analyses were carried out using the statistical software program EPIDAT 3.1. (Table [3](#T3){ref-type="table"}).

Results {#s3}
=======

Study selection
---------------

The preliminary search identified 170 articles including 15 RCTs potentially responding to the inclusion criteria (Figure [1](#F1){ref-type="fig"}). Two of the RCTs were excluded because morphine was not used for postoperative analgesia (Launo et al., [@B29]; Choi et al., [@B8]) and one was excluded because the manuscript was written in Chinese (Launo et al., [@B29]). Twelve RCTs involving 569 adults were therefore included in the systematic review.

![Flow diagram of the different phases of the systematic review.](fphar-09-00921-g0001){#F1}

The effects of ketamine and remifentanil-induced hyperalgesia have been analyzed in two relatively recent meta-analyses: one by Liu et al. ([@B32]) in 2012 and another by Wu et al. ([@B58]) in 2015. Compared with Liu et al. ([@B32]), we studied five additional RCTs and excluded seven (Liu et al., [@B32]), while compared with Wu et al. ([@B58]), we studied four additional RCTs and excluded six (Wu et al., [@B58]). The studies were excluded because they included children, NMDA receptor antagonists other than ketamine (magnesium sulfate and amantadine), or postoperative opioids other than morphine.

Study characteristics
---------------------

The 12 RCTs were published between 2002 and 2015 (Table [2](#T2){ref-type="table"}) and had been conducted in six countries: France (Moher et al., [@B40]; Clark et al., [@B11]; Maher et al., [@B33]; Launo et al., [@B29]; Ganne et al., [@B14]; Joly et al., [@B23]; Yu et al., [@B60]; Choi et al., [@B8]; Gordt et al., [@B16]; Kang et al., [@B24]), Austria (Jaksch et al., [@B22]), Jordan (Hadi et al., [@B20], [@B19]), Brazil (Leal et al., [@B30]), Korea (Lee et al., [@B31]), and Turkey (Sahin et al., [@B48]; Yalcin et al., [@B59]). Nine RCTs involving 413 patients were assigned to the major surgery group while three involving 156 patients were assigned to the minor surgery group. Although all 12 RCTs used morphine to control postoperative pain, the administration regimens varied. Eight studies administered morphine via a patient-controlled analgesia system (Schmid et al., [@B49]; Jaksch et al., [@B22]; Sahin et al., [@B48]; Joly et al., [@B23]; Hadi et al., [@B20], [@B19]; Kim et al., [@B25]; Lee et al., [@B31]; Roeckel et al., [@B47]; one of these also used paracetamol, Ganne et al., [@B14]) and two did not specify the type of pump (Reddi, [@B46]) or infusion system used (Van Elstraete et al., [@B55]).

Synthesis of results
--------------------

We were unable to assess the incidence of psychotic events in minor surgery (subgroup 15) by meta-analysis because only one of the studies yielded a result other than 0. The characteristics of the 16 subgroups are shown in Table [3](#T3){ref-type="table"}, together with the results of the heterogeneity and publication bias tests. Subgroups 2, 14, and 16 were homogeneous and the rest were heterogeneous. Risk of publication bias was detected in subgroups 5, 9, 10, and 11, and their results should, therefore, be interpreted with caution. The results of the meta-analysis are summarized in Table [4](#T4){ref-type="table"}.

###### 

Meta-analysis results.

  **Subgroup**                                   **Results**                     **Forest plot**                                             
  ---------------------------------------------- ------------------------------- ----------------- ------------------------------- --------- -------------------------------
  VAS 0--2 h Minor surgery                       Van Elstraete, −30 min (2004)   40                −7.83 (−9.65; −6.0027)          16.7362   ![](fphar-09-00921-i0001.jpg)
                                                 Van Elstraete, −1 h (2004)      40                −23.5538 (−28.752218.3553)      9.3902    
                                                 Van Elstraete, −2 h (2004)      40                3.6858 (2.667; 4.7038)          18.1041   
                                                 Leal, −2 h (2015)               56                0.5411 (0.0078; 1.0744)         18.6037   
                                                 Leal, −30 min (2015)            56                −1.2014 (−1.7706; 0.6323)       18.5768   
                                                 Leal, −1 h (2015)               56                −0.9581 (−1.5112; −0.4051)      18.5890   
                                                 Random effects                  288               −3.1549 (−5.4066; −0.9033)                
  VAS 0--2 h Major surgery                       Jaksch, −1 h (2002)             30                −0.4071 (−1.1302; 0.3159)       21.0181   ![](fphar-09-00921-i0002.jpg)
                                                 Jaksch, −2 h (2002)             30                −0.7381 (−1.4778; 0.0015)       20.0857   
                                                 Aubrun, 0--30 min (2008)        90                −0.8615 (−1.2935; 0.4296)       58.8962   
                                                 Fixed effects                   150               −0.7412(−1.0727; −0.4098)                 
  VAS 4 h Minor surgery                          Van Elstraete, [@B54]           40                −2.1788 (−2.9612; 1.3964)       31.8379   ![](fphar-09-00921-i0003.jpg)
                                                 Leal et al., [@B30]             56                −0.3301 (−0.8575; 0.1973)       34.5329   
                                                 Random effects                  96                −1.2309 (−3.0421; 0.5802)                 
  VAS 4 h Mayor surgery                          Joly et al., [@B23]             49                −1.7351 (−2.3922; 1.0781)       31.7254   ![](fphar-09-00921-i0004.jpg)
                                                 Ganne et al., [@B14]            61                0.2193 (−0.2841; 0.7228)        33.6892   
                                                 Aubrun et al., [@B3]            90                −0.6174 (−1.0403; 0.1945)       34.5854   
                                                 Random effects                  200               −0.6901 (−1.6751; 0.2948)                 
  VAS 12 h Minor surgery                         Van Elstraete, [@B54]           40                −0.6143 (−1.2485; 0.0199)       27.2404   ![](fphar-09-00921-i0005.jpg)
                                                 Hadi et al., [@B19]             30                −12.7851 (−16.0984; −9.4719)    19.7066   
                                                 Hadi et al., [@B19]             30                −4.9236 (−6.3604; −3.4869)      25.6965   
                                                 Leal et al., [@B30]             56                0.5562 (0.0224; 1.0901)         27.3564   
                                                 Random effects                  156               −3.7999 (−6.5450; −1.0548)                
  VAS 12 h Major surgery                         Joly et al., [@B23]             49                2.3720 (1.6410; 3.1029)         32.8124   ![](fphar-09-00921-i0006.jpg)
                                                 Ganne et al., [@B14]            61                0.5523 (0.0408; 1.0637)         33.5299   
                                                 Aubrun et al., [@B3]            90                −1.4282 (−1.8910; −0.9653)      33.6576   
                                                 Random effects                  200               0.4828 (−1.5621; 2.5276)                  
  VAS 24 h Minor surgery                         Van Elstraete, [@B54]           40                −2.6816 (−3.5357; −1.8275)      26.1858   ![](fphar-09-00921-i0007.jpg)
                                                 Hadi et al., [@B19]             30                −15.8746 (−19.9546; −11.7946)   22.5099   
                                                 Hadi et al., [@B19]             30                −8.4976 (−10.7637--6.2315)      25.9533   
                                                 Leal et al., [@B30]             56                2.4906 (1.7926; 3.1886)         26.2510   
                                                 Random effects                  156               −5.7507 (−10.8028; −0.6986)               
  VAS 24 h Major surgery                         Joly et al., [@B23]             49                2.5823 (1.8239; 3.3407)         32.6371   ![](fphar-09-00921-i0008.jpg)
                                                 Ganne et al., [@B14]            60                0.4164 (−0.0951; 0.9279)        33.5812   
                                                 Aubrun et al., [@B3]            90                −1.1166 (−1.5609; −0.6724)      33.7817   
                                                 Random effects                  199               0.6054 (−1.3021; 2.5130)                  
  Morphine consumption minor surgery             Van Elstraete, [@B54]           40                −1.0657 (−1.7280; −0.4033)      35.1136   ![](fphar-09-00921-i0009.jpg)
                                                 Hadi et al., [@B19]             30                −19.3089 (−24.2468; −14.3710)   22.1079   
                                                 Hadi et al., [@B19]             30                −48.2743 (−60.5101; −36.0385)   7.5228    
                                                 Leal et al., [@B30]             56                −0.1003 (−0.6244; 0.4239)       35.2556   
                                                 Random effects                  156               −8.3099 (−12.0904; −4.5295)               
  Morphine consumption major surgery             Sahin et al., [@B48]            33                1.0361 (0.3091; 1.7631)         17.3244   ![](fphar-09-00921-i0010.jpg)
                                                 Ganne et al., [@B14]            61                0.6916 (0.1748; 1.2083)         17.4153   
                                                 Aubrun et al., [@B3]            90                2.6299 (2.0657; 3.1942)         17.3974   
                                                 Hadi et al., [@B20]             30                −7.3485 (−9.3408; 5.3561)       16.2113   
                                                 Guignard et al., [@B18]         50                −12.5382 (−15.0574; −10.0190)   15.5224   
                                                 Yalcin et al., [@B59]           53                −10.4428 (−12.5024; −8.3831)    16.1292   
                                                 Random effects                  317               −4.0644 (−7.0110; −1.1178)                
  Time to first rescue analgesia minor surgery   Van Elstraete, [@B54]           40                0.3305 (−0.2935; 0.9545)        34.1311   ![](fphar-09-00921-i0011.jpg)
                                                 Hadi et al., [@B19]             30                14.6007 (10.8376; 18.3638)      32.9752   
                                                 Hadi et al., [@B19]             30                15.1306 (11.2358; 19.0254)      32.8937   
                                                 Random effects                  100               9.9044 (−1.6756; 214845)                  
  Time to first rescue analgesia mayor surgery   Jaksch et al., [@B22]           30                −1.2545 (−2.0374; −0.4716)      25.8794   ![](fphar-09-00921-i0012.jpg)
                                                 Guignard et al., [@B18]         50                8.85487.0329; 10.6767           25.3153   
                                                 Sahin et al., [@B48]            33                −2.6495 (−3.5847; −1.7143)      25.823    
                                                 Joly et al., [@B23]             49                19.9587 (15.9676; 23.9497)      22.9816   
                                                 Random effects                  162               5.8196 (0.2130; 11.4261)                  
  Incidence of ponv minor surgery                Van Elstraete, [@B54]           40                1.3333 (0.3413; 5.2085)         15.8739   ![](fphar-09-00921-i0013.jpg)
                                                 Hadi et al., [@B19]             30                0.1250 (0.0178; 0.8802)         8.4422    
                                                 Hadi et al., [@B19]             30                0.6250 (0.2650; 1.4741)         32.0743   
                                                 Leal et al., [@B30]             56                0.5000 (0.2564; 0.9749)         43.6096   
                                                 Random effects                  156               0.5583 (0.3084; 1.0105)                   
  Incidence of ponv major surgery                Guignard et al., [@B18]         50                0.80008 (0.2428; 2.6355)        7.0831    ![](fphar-09-00921-i0014.jpg)
                                                 Jaksch et al., [@B22]           30                1.7500 (0.6448; 4.7497)         10.0983   
                                                 Joly et al., [@B23]             49                1.0417 (0.4661; 2.3279)         15.5688   
                                                 Ganne et al., [@B14]            61                1.7222 (0.4508; 6.5802)         5.6030    
                                                 Aubrun et al., [@B3]            90                1.0000 (0.6676; 1.4980)         61.6469   
                                                 Fixed effects                   280               1.0806 (0.7868; 1.4841)                   
  Incidence of psycotic events major surgery     Yalcin et al., [@B59]           30                1.0000 (0.0687; 14.553)         20.7547   ![](fphar-09-00921-i0015.jpg)
                                                 Aubrun et al., [@B3]            90                1.6667 (0.4233; 6.5617)         79.2453   
                                                 Fixed effects                   120               1.4990 (0.4426; 5.0771)                   

*PONV, Postoperative nausea and vomiting; RR, Risk ratio. Subgroup 15 was excluded from the meta-analysis*.

### Cumulative morphine consumption

Nine of the 12 RCTs reported cumulative morphine consumption as an outcome measure for assessing ketamine efficacy at 24 h. The data were heterogeneous in the minor and major surgery groups (*p* \< 0.001). As indicated by the forest plot (Figure [1](#F1){ref-type="fig"}), morphine consumption in the first 24 h was significantly lower in the intervention group than in the control group in patients who underwent both minor surgery (SMD = −8.3099, 95% CI: −12.0904 to −4.5295) and major surgery (SMD = −4.0644, 95% CI: −7.0110 to −1,1178). In the case of minor surgery, the sensitivity analysis showed that the elimination of the studies by Van Elstraete et al. and Leal et al. would moderately change the global effect and lead to larger CI, but it would not change the statistical significance and the conclusions. In major surgery, only the elimination of the study by Guignard et al. ([@B18]) would lead to a loss of statistical significance (Annex 2 in [Supplementary Material](#SM1){ref-type="supplementary-material"}).

### Postoperative pain intensity

Eight RCTs involving 475 patients reported data on pain intensity at rest in the first 24 postoperative hours. The data were heterogeneous at all points of follow-up except for the first 2 h in the minor surgery group. The forest plots showed a significant decrease in pain intensity with ketamine and morphine compared with morphine only in the minor surgery group at 2, 12, and 24 h and in the major surgery group at 2 h (Table [4](#T4){ref-type="table"}). Pain intensity in the first 24 h was significantly lower with ketamine in the minor surgery group (SMD = −5.7507, 95% CI: −10.8028 to −0.6986) but not in the major surgery group (Table [4](#T4){ref-type="table"}). According to the sensitivity analysis, removing the studies by Van Elstraete et al. and Hadi et al. would lead to a loss of statistical significance in some cases. On the other hand, the elimination of the study by Ganne et al. in the case of pain intensity after 4 h in major surgery would make the result statistically significant, showing favorable results for the ketamine group (Annex 2 in [Supplementary Material](#SM1){ref-type="supplementary-material"}).

### Time to first rescue analgesia

Six RCTs involving 262 patients reported data on time of the first request for analgesia in the postoperative period. There were three RCTs (100 patients) in the minor surgery group and four (162 patients) in the major surgery group, and both groups were affected by significant heterogeneity (*p* \< 0.001). The forest plot shows a significantly longer time to the first rescue analgesia for ketamine in the major surgery group (SMD = 5.8196, 95% CI: 0.2130--11.4261) but not in the minor surgery group (Table [4](#T4){ref-type="table"}). However, if the study by Van Elstraete et al. would be removed, the results of minor surgery would be statistically significant (Annex 2 in [Supplementary Material](#SM1){ref-type="supplementary-material"}).

### Adverse effects

Eight RCTs involving 326 patients reported on PONV, while two involving 120 patients reported on psychotic events (Table [4](#T4){ref-type="table"}). According to the pooled analysis, ketamine administration was not a protective or risk factor for the occurrence of adverse effects, since all the CIs for the overall measure contained the value RR = 1, indicating no differences between the intervention and the control group.

Discussion {#s4}
==========

Postoperative opioid-induced hyperalgesia can have significant clinical consequences, including inadequate pain control, increased opioid consumption, and a greater risk of adverse effects, ultimately leading to higher morbidity, longer hospital stays, and a greater likelihood of chronic postsurgical pain (Fletcher and Martinez, [@B12]). Opioid-induced hyperalgesia is believed to be due to changes in the central and peripheral nervous systems that result in sensitization of the pronociceptive pathways. Numerous mechanisms have been implicated in the pathophysiology of this condition, notably those involving the central glutamatergic system, since the NMDA receptor antagonism prevents the opioid-induced pain sensitivity and the perturbation of spinal glutamate transporter activity modulates the development of opioid-induced hyperalgesia. The activation of spinal dynorphin content, and the increase in the evoked release of spinal excitatory neuropeptides such as calcitonin gene-related peptide from primary afferents is also evoked. Other phenomena involved are related to neuroplastic changes in the rostral ventromedial medulla that would increase the activity of the facilitating descending nociceptive pathways. In addition, peripheral sensitization involving the activity of protein kinase C is also involved (Chu et al., [@B10]). The existence of multifactorial pathogenic features could explain the conflicting results reported for the efficacy of ketamine to date, as this anesthetic alone may not be able to block central sensitization and prevent opioid-induced hyperalgesia (Roeckel et al., [@B47]).

Low remifentanil doses (≥0.1 μg/kg/min or ≥2.7 ng/ml) appear to be sufficient for inducing hyperalgesia (Kim et al., [@B25]). We analyzed 12 RCTs comparing remifentanil-based general anesthesia (with doses ranging from 0.01 to 0.5 μg/kg/min or 2--4 ng/ml) with and without low-dose ketamine (infusion \<1.2 mg/kg/h or bolus injection \<1 mg/kg) (Kim et al., [@B25]).

Our systematic review is the first to analyze the effects of ketamine sedation according to the type of surgery (major vs. minor). Minor surgical procedures were defined as procedures that required a minimum hospital stay, such as arthroscopy, laparoscopy, and microsurgery. Although greater pain intensity might be expected after major surgery due to the size of the surgical field, the intensity of the nociceptive stimuli, and the longer operative times, a high incidence of postoperative pain has also been reported for laparoscopic and other minor procedures (Gerbershagen et al., [@B15]). In our study, the favorable results observed for ketamine vs. no ketamine in the first 2, 12, and 24 h in the minor surgery group (Table [4](#T4){ref-type="table"}) may be related to the fact that lower doses of analgesia are used for minor procedures and they may have been insufficient to relieve postoperative pain in the control group.

Remifentanil-based general anesthesia does not offer sufficient guarantees for adequate postoperative pain management in major or minor surgery without the application of multimodal analgesic **regimens** adapted to each procedure. If the necessary analgesic effect is not achieved, activation of NMDA receptors during surgery could give rise to an erroneous interpretation of results (Van Elstraete, [@B54]).

Our findings show that perioperative ketamine was associated with a significant reduction in the consumption of morphine 24 h after minor and major surgery. Conflicting results have been reported in the literature. In a meta-analysis of RCTs involving 649 adults and children and adults who underwent spine surgery, Pendi et al. ([@B43]) reported that perioperative ketamine significantly reduced morphine consumption and pain intensity. However, another meta-analysis of 11 studies examining the use of ketamine in children did not find any significant reduction in morphine consumption. The differences could be due to different pharmacokinetic profiles in children and adults or to variations in anesthetic regimens and pain scales (Michelet et al., [@B37]).

Our findings on morphine consumption should be interpreted with caution, as the publication bias analysis showed a risk of bias in both the minor and major surgery subgroups. Although the results for some of the subgroups could have been improved by removing certain studies, we did not do this because this would have introduced an additional source of bias and because the sensitivity analysis supported the robustness of the meta-analysis results (data not shown).

Apart from exerting a morphine-sparing effect, ketamine also significantly reduced pain intensity in the early postoperative period after major and minor surgery, supporting results from previous meta-analyses of NMDA receptor antagonists, including magnesium sulfate (Liu et al., [@B32]; Wu et al., [@B58]). The effects of remifentanil-induced hyperalgesia appear to be greatest during this early postoperative period (Fletcher and Martinez, [@B12]) and ketamine may help to reduce pain at this time because it provides residual analgesia in relation to its relatively rapid clearance (890--1,227 mL/min) and short elimination half-life (2--3 h) (Mion and Villevieille, [@B39]).

In their meta-analysis of 14 RCTs involving 623 patients, Wu et al. ([@B58]) observed no differences in morphine consumption or time to first rescue analgesia between patients who received an NMDA receptor (ketamine or magnesium sulfate) and controls. Conflicting findings from meta-analyses on the efficacy of ketamine in preventing remifentanil-induced hyperalgesia have been attributed to the inclusion of RCTs examining several NMDA antagonists (Liu et al., [@B32]). In order to avoid that, we decided to minimize sources of variability by excluding studies of all NMDA receptor antagonists other than ketamine. The variations observed in the anesthesia and analgesia protocols in the RCTs included in our systematic review can be explained by the fact that the studies were from six countries (Table [2](#T2){ref-type="table"}).

Conceptually, general anesthesia can be maintained during surgery by total intravenous anesthesia (TIVA) or balanced anesthesia (inhalation of volatile agents). Four of the RCTs in our study used TIVA (with propofol) (Jaksch et al., [@B22]; Van Elstraete et al., [@B55]; Ganne et al., [@B14]) while eight used volatile agents (Schmid et al., [@B49]; Sahin et al., [@B48]; Joly et al., [@B23]; Hadi et al., [@B20]). Propofol has traditionally been considered to be a hypnotic sedative without analgesic properties, although there is evidence that it might have a modulatory effect on nociceptive processing and perception (Bandschapp et al., [@B4]), reflected in the observation of less intense postoperative pain compared with general balanced anesthesia (Cheng et al., [@B7]). The potential modulatory role of propofol in opioid-induced hyperalgesia may be due to its interaction with GABA-A receptors at the supraspinal level (Wang et al., [@B56]; Singler et al., [@B52]), to its non-competitive inhibition of NMDA (in particular the NR1 subunit) (Orser et al., [@B41]; Kingston et al., [@B27]), or to its neuroprotective effects (demonstrated in animal models) (Grasshoff and Gillessen, [@B17]). Propofol could reduce hyperalgesia induced by high doses of remifentanil during maintenance of intravenous anesthesia (Shin et al., [@B50]) and consequently improve postoperative outcomes and consumption of morphine. As shown by the influence graph for pain intensity in the minor surgery group, only one of the studies would have substantially modified the overall result had it been eliminated from the meta-analysis and this was the propofol-based anesthesia article by Van Elstraete et al. ([@B55]). Its removal would have eliminated the statistical difference between the ketamine and control groups at 30 min, 1, 12, and 24 h, generating inconclusive results.

We found no significant differences between patients who received preemptive ketamine and those who did not for opioid-related adverse effects or ketamine-related psychotomimetic effects. Our findings thus support previous findings (Assouline et al., [@B2]) that subanesthetic doses of perioperative ketamine are safe.

The findings of this systematic review and meta-analysis show that, when used as an adjuvant to morphine, ketamine reduces postoperative morphine consumption and pain intensity in the early postoperative period in adults undergoing major and minor surgery. Our study has some limitations, including (1) possible confounding by the high prevalence of postoperative pain; (2) the variability of anesthetic regimens and study populations together with the individual variability reflected in the different subgroups; (3) the multifactorial pathogenesis of opioid-induced hyperalgesia together with the lack of a protocol for the objective measurement of different types of hyperalgesia; and (4) the lack of standardized, clearly defined scales to measure postoperative pain, morphine consumption, and ketamine- and opioid-related adverse effects. These limitations should be taken into account when designing future RCTs.

Conclusions {#s5}
===========

In summary, our systematic review and meta-analysis provide evidence that subanesthetic intraoperative doses of ketamine have a beneficial effect on pain control in the immediate postoperative period (24 h), as they reduce the consumption of postoperative morphine and the intensity of pain following minor and major surgery. The addition of low doses of ketamine to remifentanil-based general anesthesia regimens should be considered.

While our findings may help to explain some of the conflicting evidence on the use of preemptive ketamine, postoperative pain management remains a challenge and further research using standardized protocols and scales is needed.
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